Protagonist Therapeutics Hits New 52-Week High at $62.21

Protagonist Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 62.21 on September 18, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly noteworthy given its small-cap status with a market capitalization of USD 3,496 million.
Over the past year, Protagonist Therapeutics has demonstrated impressive growth, with a remarkable 87.34% increase in stock price, significantly outperforming the S&P 500, which recorded a 17.14% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 60.00, reflecting its valuation in the market. Additionally, Protagonist Therapeutics maintains a return on equity of 7.79%, indicating effective management of shareholder equity.

Despite a debt-to-equity ratio of -0.85, which suggests a unique financial structure, the company has not distributed dividends, maintaining a yield of 0.00%. The stock's previous 52-week low was recorded at USD 33.31, highlighting the substantial upward movement in its price. This performance reflects the company's position within the competitive landscape of the pharmaceuticals and biotechnology industry.